Clinical Research Directory

Inclusion Criteria: * Able to understand written informed consent * Willing and able to comply with study requirements * Willing to comply with protocol-specified contraception requirements * Healthy male or non-pregnant, non-lactating female of non-childbearing potential per Investigator assessment. * Body mass index (BMI) of 18.0 to 30.0 kg/m\^2 at screening * Weight of at least 50 kg at screening Exclusion Criteria: * Serious adverse reaction or hypersensitivity to any drug or formulation excipients * History of clinically significant allergy requiring treatment * History of clinically significant cardiovascular, renal, hepatic, dermatological, chronic respiratory or gastrointestinal (GI) disease, neurological or psychiatric disorder * Any form of cancer within the 5 years before the first does of this study * History and/or symptoms of adrenal insufficiency * History of clinically significant GI disease * Condition or history of a condition that could be aggravated by glucocorticoid antagonism or glucocorticoid activation * History of additional risk factors for torsades de pointes * Poor venous access that limits phlebotomy * Clinically significant abnormal clinical chemistry, hematology or urinalysis * History or evidence of hypokalemia * Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) 1 and 2 antibody results * Evidence of renal impairment at screening * Positive serum or highly sensitive urine pregnancy test at screening or first admission * Clinically significant ECG abnormalities or vital sign abnormalities at screening or baseline * Received any investigational medicinal products (IMP) in a clinical research study within 5 half-lives or within 30 days prior to first dose * Donation of blood within 2 months or donation of plasma within 1 week prior to first dose of study medication * Are taking, or have taken, any prescribed or over-the-counter drug or vitamins/herbal remedies in the 14 days before first IMP administration * Currently using glucocorticoids or have a history of systemic glucocorticoid use at any dose within the last 12 months before first IMP administration or 3 months for inhaled products * History of any drug or alcohol abuse in the past 2 years * Regular alcohol consumption as defined in the study protocol * A confirmed positive alcohol urine test at screening or first admission * Current smokers and those who have smoked within the last 12 months * Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months * A confirmed positive urine cotinine test at screening or first admission * Positive drug screen test result at screening or first admission * Male subjects with pregnant or lactating partners * Study site or Sponsor employee or immediate family members one * Failure to satisfy the Investigator of fitness to participate for any other reason.